mRNA expression and western blotting indicated that, with the exception of LRP1 in 22Rv1, all components of the LRP1-Met-IQSEC1-ARF5/6 pathway are expressed in examined prostate cancer cell lines (Supplementary Fig. 9a, b). Here, ARF5 is linked to prostate carcinoma.